In:
Diabetes, American Diabetes Association, Vol. 67, No. Supplement_1 ( 2018-07-01)
Abstract:
Metabolomic profiling has identified signatures of insulin resistance in skeletal muscle; however, the direct effect of insulin stimulation on these metabolite signatures in humans remains largely unresolved. To address this, we investigated the effect of insulin stimulation on skeletal muscle metabolites in a well characterized cohort of humans spanning the spectrum of insulin sensitivity. Vastus lateralis muscle samples were obtained from endurance athletes, sedentary lean and obese adults, and individuals with type 2 diabetes (n=16,15,15,12, respectively) under basal conditions and 1-hour into a hyperinsulinemic-euglycemic clamp. Metabolomic analysis was performed using UPLC-MS/MS. Basal concentrations of TCA cycle intermediates, including citrate, alpha-ketoglutarate, succinate, fumarate, malate and oxaloacetate, were positively related to insulin sensitivity (steady-state clamp Rd glucose in mg/kg/min; all P & lt;0.01). Most of these relationships strengthened during insulin stimulation, with the strongest relationships observed for malate (r2 = 0.453, P & lt;0.01) and fumarate (r2 = 0.501, P & lt;0.01) that reflected a blunted increase in TCA intermediates during insulin stimulation with insulin resistance. Insulin stimulation lowered most medium- and long-chain acyl-carnitines compared with basal levels; however, this effect was also attenuated as a function of insulin resistance, signaling impaired metabolic flexibility. Notably, basal levels of several acyl-carnitines, including C12:0, C14:0, C16:0 and C18:1, were increased in endurance athletes compared with other groups (all P & lt;0.05). Several amino acids, including leucine, isoleucine and lysine, were negatively related to insulin sensitivity in the basal and insulin stimulated state (all P & lt;0.01). Together these findings indicate that physiologic insulin stimulation exacerbates metabolic signatures of skeletal muscle insulin resistance in humans. Disclosure S.A. Newsom: None. L. Perreault: Advisory Panel; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Novo Nordisk A/S. Advisory Panel; Self; Merck & Co., Inc.. Speaker's Bureau; Self; Merck & Co., Inc., AstraZeneca, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc.. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Sanofi. Speaker's Bureau; Self; Sanofi. A. Kerege: None. K.A. Harrison: None. D.E. Kahn: None. T. Nemkov: None. A. D’Alessandro: None. B. Bergman: Research Support; Self; Eli Lilly and Company. Advisory Panel; Spouse/Partner; Novo Nordisk Inc., Merck & Co., Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company.
Type of Medium:
Online Resource
ISSN:
0012-1797
,
1939-327X
Language:
English
Publisher:
American Diabetes Association
Publication Date:
2018
detail.hit.zdb_id:
1501252-9
Permalink
